Resources Management Corp CT ADV Reduces Holdings in Natera, Inc. $NTRA

Resources Management Corp CT ADV trimmed its stake in Natera, Inc. (NASDAQ:NTRA) by 27.6% in the 4th quarter, HoldingsChannel reports. The firm owned 6,758 shares of the medical research company’s stock after selling 2,582 shares during the quarter. Resources Management Corp CT ADV’s holdings in Natera were worth $1,548,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Palladiem LLC purchased a new position in Natera during the 4th quarter valued at about $31,000. Horizon Investments LLC purchased a new position in Natera during the 3rd quarter valued at about $32,000. Bank of Jackson Hole Trust lifted its position in Natera by 103.8% during the 4th quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock valued at $37,000 after acquiring an additional 83 shares during the period. Flagship Harbor Advisors LLC purchased a new position in Natera during the 4th quarter valued at about $41,000. Finally, Greenline Wealth Management LLC purchased a new position in Natera during the 4th quarter valued at about $41,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

NTRA has been the subject of a number of recent research reports. Morgan Stanley lowered their price target on shares of Natera from $265.00 to $250.00 and set an “overweight” rating for the company in a research report on Tuesday, March 3rd. William Blair initiated coverage on shares of Natera in a research report on Tuesday, April 14th. They set an “outperform” rating for the company. Royal Bank Of Canada initiated coverage on shares of Natera in a research report on Thursday. They set an “outperform” rating and a $275.00 price target for the company. Wells Fargo & Company lifted their price target on shares of Natera from $215.00 to $220.00 and gave the company an “equal weight” rating in a research report on Friday, May 8th. Finally, Evercore reissued an “outperform” rating and set a $270.00 price target on shares of Natera in a research report on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $256.53.

Natera Stock Performance

NASDAQ:NTRA opened at $212.07 on Monday. The firm has a market cap of $30.37 billion, a P/E ratio of -130.10 and a beta of 1.56. Natera, Inc. has a fifty-two week low of $131.81 and a fifty-two week high of $256.36. The firm has a 50-day simple moving average of $206.49 and a two-hundred day simple moving average of $215.83.

Insider Buying and Selling at Natera

In other Natera news, CEO Steven Leonard Chapman sold 41,124 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $221.03, for a total transaction of $9,089,637.72. Following the completion of the sale, the chief executive officer directly owned 108,743 shares in the company, valued at approximately $24,035,465.29. This trade represents a 27.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Solomon Moshkevich sold 3,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $218.43, for a total transaction of $655,290.00. Following the sale, the insider owned 137,643 shares of the company’s stock, valued at approximately $30,065,360.49. This represents a 2.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 159,378 shares of company stock worth $34,640,860 in the last 90 days. Insiders own 5.05% of the company’s stock.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.